SG10201704913RA - Methods, compositions, and formulations for preventing or reducing adverse effects in a patient - Google Patents

Methods, compositions, and formulations for preventing or reducing adverse effects in a patient

Info

Publication number
SG10201704913RA
SG10201704913RA SG10201704913RA SG10201704913RA SG10201704913RA SG 10201704913R A SG10201704913R A SG 10201704913RA SG 10201704913R A SG10201704913R A SG 10201704913RA SG 10201704913R A SG10201704913R A SG 10201704913RA SG 10201704913R A SG10201704913R A SG 10201704913RA
Authority
SG
Singapore
Prior art keywords
formulations
patient
compositions
preventing
methods
Prior art date
Application number
SG10201704913RA
Inventor
Dennis T Mangano
Original Assignee
Pericor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pericor Therapeutics Inc filed Critical Pericor Therapeutics Inc
Publication of SG10201704913RA publication Critical patent/SG10201704913RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
SG10201704913RA 2005-03-28 2006-03-28 Methods, compositions, and formulations for preventing or reducing adverse effects in a patient SG10201704913RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66607105P 2005-03-28 2005-03-28

Publications (1)

Publication Number Publication Date
SG10201704913RA true SG10201704913RA (en) 2017-07-28

Family

ID=37054068

Family Applications (3)

Application Number Title Priority Date Filing Date
SG201001929-7A SG160425A1 (en) 2005-03-28 2006-03-28 Methods, compositions, and formulations for preventing or reducing adverse effects in a patient
SG2013069885A SG194352A1 (en) 2005-03-28 2006-03-28 Methods, compositions, and formulations for preventing or reducing adverse effects in a patient
SG10201704913RA SG10201704913RA (en) 2005-03-28 2006-03-28 Methods, compositions, and formulations for preventing or reducing adverse effects in a patient

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG201001929-7A SG160425A1 (en) 2005-03-28 2006-03-28 Methods, compositions, and formulations for preventing or reducing adverse effects in a patient
SG2013069885A SG194352A1 (en) 2005-03-28 2006-03-28 Methods, compositions, and formulations for preventing or reducing adverse effects in a patient

Country Status (14)

Country Link
US (3) US8993527B2 (en)
EP (3) EP3132796A1 (en)
JP (8) JP2008534601A (en)
KR (1) KR20070121026A (en)
CN (1) CN101184495B (en)
AU (1) AU2006230242B2 (en)
BR (1) BRPI0608654C1 (en)
CA (1) CA2602291C (en)
MX (1) MX2007012045A (en)
NO (1) NO342207B1 (en)
NZ (1) NZ561649A (en)
SG (3) SG160425A1 (en)
WO (1) WO2006105167A2 (en)
ZA (1) ZA200708277B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG160425A1 (en) 2005-03-28 2010-04-29 Pericor Therapeutics Inc Methods, compositions, and formulations for preventing or reducing adverse effects in a patient
US20070082859A1 (en) * 2005-10-07 2007-04-12 Stover Richard R Formulations of AICA riboside
WO2008086341A1 (en) * 2007-01-09 2008-07-17 Pericor Therapeutics, Inc. Methods. compositions, and formulations for preventing or reducing adverse effects in a patient
DE102008007216A1 (en) 2007-05-29 2008-12-11 Samsung Electro - Mechanics Co., Ltd., Suwon Printed circuit board and manufacturing method thereof
CA2739463C (en) * 2008-10-03 2018-07-03 Pericor Therapeutics, Inc. Methods and compositions for treatment of acute heart failure
US8489182B2 (en) 2011-10-18 2013-07-16 General Electric Company System and method of quality analysis in acquisition of ambulatory electrocardiography device data
US11160879B2 (en) 2014-01-15 2021-11-02 Masamichi Yamamoto Transgenic animal for visualization of ATP and use thereof
WO2015127315A1 (en) 2014-02-20 2015-08-27 Otitopic Inc. Dry powder formulations for inhalation
CN104140438B (en) * 2014-06-11 2017-01-18 苏州景泓生物技术有限公司 Synthesis method of 5-formamidoimidazole-4-carboxamide ribotide analogue
PL3179986T3 (en) * 2014-07-31 2023-06-26 Vectura Inc. Dry powder formulations for inhalation
WO2016176552A1 (en) 2015-04-30 2016-11-03 Otitopic Inc. Dry power formulations for inhalation
WO2018092911A1 (en) * 2016-11-21 2018-05-24 株式会社スタージェン Intracellular atp enhancer
JP6937134B2 (en) 2016-11-21 2021-09-22 株式会社スタージェン Intracellular ATP enhancer
WO2019039438A1 (en) * 2017-08-21 2019-02-28 国立大学法人三重大学 Observation method using non-human mammalian cerebral infarction model, and observation device using non-human mammalian cerebral infarction model
WO2021072322A1 (en) * 2019-10-09 2021-04-15 Mayo Foundation For Medical Education And Research Treatment for gastrointestinal disorders

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1645976A1 (en) 1966-06-18 1971-01-21 Ajinomoto Kk Process for the preparation of adenosine and 2 ', 3'-O-isopropylidene adenosine
JPS4944349B1 (en) 1967-06-16 1974-11-27
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
AT350735B (en) 1976-08-06 1979-06-11 Hoffmann La Roche METHOD FOR PRODUCING NEW RIBO-FURANOSYL IMIDAZOLE DERIVATIVES
EP0066909A3 (en) 1981-05-15 1984-03-07 FISONS plc Imidazole derivatives, pharmaceutical compositions containing them and processes for their production
US4575498A (en) 1983-07-21 1986-03-11 Duke University Method for restoring depleted purine nucleotide pools
US5030623A (en) 1986-03-27 1991-07-09 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells
US5118601A (en) 1986-03-27 1992-06-02 The Regents Of The University Of California Method of screening purine nucleoside compounds or analogs for the ability to enhance the cellular synthesis and release of adenosine
AU5668886A (en) 1986-03-27 1987-10-20 Harry Edward Gruber A method of increasing adenosine excretion
US4912092A (en) 1986-03-27 1990-03-27 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells
US5008251A (en) 1986-03-27 1991-04-16 The Regents Of The University Of California Method of treating autism
US5658889A (en) 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
US5200525A (en) 1989-01-24 1993-04-06 Gensia Pharmaceuticals Anti-seizure compounds
US5132291A (en) 1989-01-24 1992-07-21 Gensia Pharmaceuticals, Inc. Antivirals and methods for increasing the antiviral activity of azt
US5082829A (en) 1989-01-24 1992-01-21 Gensia Pharmaceuticals AICA riboside prodrugs
US5187162A (en) 1989-09-15 1993-02-16 Gensia Pharmaceuticals Methods of treating neurodegenerative conditions
US5646128A (en) 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
IL99124A (en) 1990-08-10 1998-02-22 Gensia Pharma Substituted imidazole analogs of aica riboside
US5777100A (en) 1990-08-10 1998-07-07 Gensia Inc. AICA riboside analogs
IL99125A0 (en) * 1990-08-10 1992-07-15 Gensia Pharma Derivatives of imidazole analog of aica riboside and their use
IL103294A0 (en) 1991-09-30 1993-05-13 Gensia Pharma Pharmaceutical compositions for preventing tissue damage associated with decreased blood flow
ATE189390T1 (en) 1992-12-16 2000-02-15 Agouron Pharma ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS
IL108524A0 (en) 1993-02-03 1994-05-30 Gensia Inc Imidazodiazepine analogs
US5366960A (en) 1993-08-26 1994-11-22 Warner-Lambert Company Method of treating cerebral and cardiovascular disorders employing [R]3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidaz 0-[4,5-d][1,3]diazepin-8-ol
US5629298A (en) 1995-03-13 1997-05-13 University Of Massachusetts Medical Center Adenosine as a positive inotrop in the compromised heart
US5645128A (en) * 1995-06-05 1997-07-08 Schwall; Charles F. Fire safety grease seal
US5998386A (en) 1997-09-19 1999-12-07 Feldman; Arthur M. Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US20040072138A1 (en) 1997-11-25 2004-04-15 Medical University Of South Carolina Attenuation of ischemia/reperfusion injury
US6103702A (en) 1999-05-24 2000-08-15 Board Of Trustees Of The University Of Illinois Use of adenosine deaminase inhibitors to treat systemic inflammatory response syndrome
US20050002943A1 (en) 2001-10-31 2005-01-06 Oberdan Leo Amp-kinase agonists or adenosine pro-drugs as immuno-stimulating agents
ES2192495B1 (en) 2002-03-21 2005-02-16 Universidad De Barcelona NEW THERAPEUTIC USE OF RIBOSIDE 5-AMINOIMIDAZOL-4-CARBOXAMIDE (ACADESIN).
SG160425A1 (en) 2005-03-28 2010-04-29 Pericor Therapeutics Inc Methods, compositions, and formulations for preventing or reducing adverse effects in a patient
US20070082859A1 (en) 2005-10-07 2007-04-12 Stover Richard R Formulations of AICA riboside
WO2008086341A1 (en) 2007-01-09 2008-07-17 Pericor Therapeutics, Inc. Methods. compositions, and formulations for preventing or reducing adverse effects in a patient
WO2009094593A1 (en) 2008-01-25 2009-07-30 Foker John E Methods and compositions for inhibiting progression to chronic cardiac failure

Also Published As

Publication number Publication date
JP2013010794A (en) 2013-01-17
WO2006105167A2 (en) 2006-10-05
AU2006230242A1 (en) 2006-10-05
EP1863497A4 (en) 2009-08-12
EP3132796A1 (en) 2017-02-22
BRPI0608654C1 (en) 2021-05-25
AU2006230242B2 (en) 2013-05-30
JP2017057222A (en) 2017-03-23
NZ561649A (en) 2011-02-25
CA2602291A1 (en) 2006-10-05
SG194352A1 (en) 2013-11-29
WO2006105167A3 (en) 2007-05-10
KR20070121026A (en) 2007-12-26
JP2020152737A (en) 2020-09-24
US20170216335A1 (en) 2017-08-03
CN101184495A (en) 2008-05-21
JP2008534601A (en) 2008-08-28
NO20075400L (en) 2007-12-19
JP2022093641A (en) 2022-06-23
US9539274B2 (en) 2017-01-10
BRPI0608654B1 (en) 2020-09-29
ZA200708277B (en) 2011-03-30
MX2007012045A (en) 2008-01-16
JP2019089853A (en) 2019-06-13
BRPI0608654A2 (en) 2010-01-19
US20060293273A1 (en) 2006-12-28
JP2015057436A (en) 2015-03-26
EP2594273A1 (en) 2013-05-22
EP1863497A2 (en) 2007-12-12
US20150272978A1 (en) 2015-10-01
BRPI0608654B8 (en) 2020-10-27
CN101184495B (en) 2011-09-14
JP7093739B2 (en) 2022-06-30
US8993527B2 (en) 2015-03-31
CA2602291C (en) 2015-08-11
JP6122417B2 (en) 2017-04-26
NO342207B1 (en) 2018-04-16
SG160425A1 (en) 2010-04-29
JP2013010795A (en) 2013-01-17

Similar Documents

Publication Publication Date Title
ZA200708277B (en) Methods,compositions,and formulations for preventing or reducing adverse effects in a patient
ZA200708361B (en) Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition
HK1209729A1 (en) Compounds, compositions and methods
TWI369981B (en) Hmb compositions and uses thereof
EP1841397A4 (en) Formulations and treatments for trichology
IL209494A (en) Insulin-oligomer monoconjugates, formulations and uses thereof
IL213795A (en) Immunogenic composition comprising at least two different saccharides and vaccine comprising said immunogenic composition
GB0422525D0 (en) Dermatological compositions and methods
PT1755391E (en) Methods and compositions for treating neuropathies
IL181825A0 (en) Immunogenic composition
EP1968526A4 (en) Foamable dental compositions and methods
IL191072A0 (en) Therapeutic compositions and methods
IL186127A (en) Pharmaceutical compositions for treating depression and methods for preparing the same
EP1827095A4 (en) Compositions and methods for anti-transpiration in plants
PL1973423T3 (en) Formulation comprising a polyphenol-containing composition and isomaltulose
ZA200803283B (en) Pharmaceutical gallium compositions and methods
GB0427145D0 (en) Compositions for use in surgery
EP2099416A4 (en) Anti-calculus dental composition and methods for using same
EP1858532A4 (en) Compositions and methods for less immunogenic protein formulations
IL186337A0 (en) Stannsoporfin compositions and administration
GB0417359D0 (en) Improvements in compositions
EP1813288A4 (en) Medicinal composition, medicinal preparation, and combination preparation
HK1098059A1 (en) Composition comprising itraconazole for oral administration
EP1865777A4 (en) Stannsoporfin compositions and administration
HK1107256A1 (en) Compositions containing nicorandil, preparation method and use